Shen Zhen-ming, Zhu Mei-lan, Zhao An-quan
5th Hospital of Tangshan City, Hebei Province 063004.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004 May;24(5):415-7.
To investigate the clinical efficacy, adverse reaction and safety of Jieyu pill (JYP) in treating depression.
The randomized controlled trial was conducted in 28 patients in the treated group and 29 patients in the control group treated with maprotiline (Map). The efficacy of treatment was evaluated before treatment and 14, 28 and 42 days after treatment, with Hamilton depression rating scale (HAMD), self-rating scale for depression (SDS), self-rating scale for anxiety (SAS) and clinical global impression (CGI), the adverse reaction was assessed by Asberg Rating Scale (ARS).
JYP was effective in treating depression, the markedly effective rate being 78.8%, corresponded to that of Map (82.8%, P > 0.05). After treatment, the scores assessed by HAMD, SDS and SAS were all lower than those before treatment (P < 0.01) respectively, but comparison between the two groups showed insignificant difference (P > 0.05). However, scores of ARS were significantly lower in the treated group than that in the control group, and the efficacy index of JYP was significantly higher than that of Map (P < 0.01).
JYP in treating depression shows the efficacy corresponded to that of Map and with less adverse reaction.
探讨解郁丸治疗抑郁症的临床疗效、不良反应及安全性。
采用随机对照试验，治疗组28例，对照组29例，对照组使用麦普替林治疗。治疗前及治疗后14、28、42天采用汉密尔顿抑郁量表（HAMD）、抑郁自评量表（SDS）、焦虑自评量表（SAS）及临床总体印象量表（CGI）评估治疗效果，采用阿伯格评定量表（ARS）评估不良反应。
解郁丸治疗抑郁症有效，显效率为78.8%，与麦普替林（82.8%）相当（P>0.05）。治疗后，HAMD、SDS及SAS评分均分别低于治疗前（P<0.01），但两组间比较差异无统计学意义（P>0.05）。然而，治疗组ARS评分显著低于对照组，解郁丸的疗效指数显著高于麦普替林（P<0.01）。
解郁丸治疗抑郁症疗效与麦普替林相当，且不良反应较少。
